Investing.com - Seelos Therapeutics (NASDAQ: SEEL) reported first quarter EPS of $-0.120, worse than the analyst estimate of $-0.110. Revenue for the quarter came in at $808K versus the consensus estimate of $0.
Seelos Therapeutics's stock price closed at $0.910. It is up 22.280% in the last 3 months and up 50.370% in the last 12 months.
Seelos Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Seelos Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Seelos Therapeutics's Financial Health score is "weak performance".
Check out Seelos Therapeutics's recent earnings performance, and Seelos Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar